Moreover, it has been recently reported that crizotinib nanomicelles effectively enhanced doxorubicin-elicited anticancer efficacy in a p53Y220C pancreatic cancer via the degradation of the p53 mutant, which was induced by crizotinib [26]. The gene discussed is TP53; the disease is pancreatic neoplasm.